摘要
目的:探讨左乙拉西坦(Lev)添加剂量治疗难治性癫癎的疗效和安全性。方法:采用开放性自身对照方法,对48例(儿童23例,成人25例)难治性癫癎患者进行Lev添加治疗,并随访1年以上,收集治疗后患者发作频率变化、无发作情况、不良反应以及退出原因。结果:Lev治疗难治性癫癎总有效率为64.58%,成人有效率高于儿童,对部分性癫癎综合征有效率高;3、6和12个月无发作率分别为6.25%、18.75%和16.67%,保留率为81.25%、56.25%和43.75%。总不良反应发生率为39.58%,无严重不良反应,退出的最主要原因为对疗效欠满意。结论:LEV是一种安全有效的难治性癫癎治疗药物,对部分性和全面性癫癎发作均有效。
Aim： To evaluate the efficacy and safety of levetiracetam （Lev） as adjunctive therapy for refractory epilepsy. Methods： An open-label, own control study were explored for 48 cases refractory epilepsy patients （23 children and 25 adults）. Patients were administered the maximum-effective Lev dose as adjunctive therapy and followed up for at least one year. The clinical data including seizure frequency, adverse effects and exit reasons were collected. Results： 64.58% patients had more than 50% reduction in seizure frequency, and the ratio in adults was higher than children＇ s. 6.25%, 18.75%, 16.67% patients got seizure free in 3 months, 6 months and 1 year, and the retention rate was 81.25%, 56.25%, 43.75% respectively. 39.58% patients reported one or more adverse effects, but no serious adverse effect appeared. The most common exit reason was not satisfying with the efficacy. Conclusion： Lev is effective and safe as adjunctive therapy for refractory epilepsy, and it is useful for both partial epilepsy and generalized epilepsy.
出处
《中国临床神经科学》
2009年第4期341-345,共5页
Chinese Journal of Clinical Neurosciences
基金
国家自然科学基金资助项目(编号:30700247)
广州市市属高校科技计划项目(编号:61021)
广州医学院第二附属医院科研立项(2007-5)
关键词
左乙拉西坦
癫痫
保留率
不良反应
抗癫痫药
levetiracetam
epilepsy
retention rate
adverse effect
antiepileptic drug
